Successful EMR-SEQ Poster presentation at ASCO 2022
Our first, already mentioned in the last newsletter, EUMelaReg abstract submission of the EMR-SEQ project (registry-based outcome analysis of 1,000 patients with BRAF V600 mutant metastatic melanoma in Europe treated with either immune checkpoint or BRAF/MEK inhibition) for the ASCO was successfully presented there. The poster received a lot of attention, and the feedback was extremely positive. We would like to pass this on to the group of authors and take this success with us as motivation for our further register work.